Evidence map›Paper›PMID 42903135›Full record

ArticleFrontiers in immunology2026

A subunit vaccine protects A129 mice from death and joint swelling against lethal Chikungunya virus challenge.

Jiangfan Li, Ting Fang, Liyuan Song, Li Qiang, Yating Hu, Chuanyi Zhao, Haoran Wang, Wenbin Zhao, Guangcheng Fu, Hongyu Yuan and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jiangfan LiNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Ting FangNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Liyuan SongLaboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang, China.
Li QiangNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Yating HuLaboratory of Advanced Biotechnology, ZJU-Hangzhou Global Scientific and Technological Innovation Center, Zhejiang University, Hangzhou, Zhejiang, China.
Chuanyi ZhaoNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Haoran WangNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Wenbin ZhaoNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Guangcheng FuNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Hongyu YuanNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.
Jianmin LiNational Key Laboratory of Advanced Biotechnology, Academy of Military Medical Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chikungunya virus (CHIKV) is primarily transmitted to humans through bites of infected Methods: We engineered mammalian cells to produce the ectodomains of the E1 and E2 glycoproteins and evaluated the protective efficacy of the resulting vaccine formulations Results: A two-dose vaccination regimen elicited high levels of antibodies and provided full protection against lethal challenge in A129 mice, preventing both death and joint swelling. Discussion: These findings demonstrate the potential of this vaccine candidate against CHIKV and warrant its further development.

Indexed as

Chikungunya FeverChikungunya virusVaccines, SubunitViral VaccinesAnimalsAntibodies, ViralDisease Models, AnimalFemaleHumansMiceProtein Subunit VaccinesVaccinationViral Envelope ProteinsAntibodies, ViralProtein Subunit VaccinesVaccines, SubunitViral Envelope ProteinsViral VaccinesChikungunya virusimmunizationprotectionsafetysubunit vaccine

Identifiers

PMID42903135
PMCPMC13680182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.